Abstract: An anti-bird roosting device for protecting an area, comprising at least a pair of cooperating base elements mounted on the area to be protected, and a plurality of projecting spikes, supported on the base elements and projecting away therefrom into a space above the area to be protected. The spikes are provided in a pattern of interspersed combinations of vertical, obtuse and acute angle-forming projections, in a high spike density that prevents roosting in the protected space. Thus, each point in the area to be protected is defended by more than one spike, each spike coming from a different direction, so as to cross-defend each other, creating a perimeter envelope defense of the air volume surrounding the base elements. Each device is easily and inexpensively prepared as a continuous mesh, whose dimensions can be constructed in standard sizes or in accordance with the needs of the user. The element diameter is typically approximately two millimeters.

Abstract: An anti-bird roosting device for protecting an area, comprising at least a pair of cooperating base elements mounted on the area to be protected, and a plurality of projecting spikes, supported on the base elements and projecting away therefrom into a space above the area to be protected. The spikes are provided in a pattern of interspersed combinations of vertical, obtuse and acute angle-forming projections, in a high spike density that prevents roosting in the protected space. Thus, each point in the area to be protected is defended by more than one spike, each spike coming from a different direction, so as to cross-defend each other, creating a perimeter envelope defense of the air volume surrounding the base elements. Each device is easily and inexpensively prepared as a continuous mesh, whose dimensions can be constructed in standard sizes or in accordance with the needs of the user. The element diameter is typically approximately two millimeters.

Abstract: A system for remotely monitoring asthma severity includes a remotely located asthma monitoring station for administering a patient self-test and for gathering test data and relevant patient information indicative of asthmatic symptoms, and a central processing facility for receiving the test data and patient information from the remote monitoring station, determining whether the test data is valid, analyzing valid test data to generate test results and an appropriate response message to the monitoring station, storing the test results in a central data repository, and disseminating the test results and response message in a timely manner as required. The monitoring system also includes a remotely located diagnosis/evaluation station for displaying the test results, response messages and other patient information.

Abstract: Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Abstract: Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Abstract: Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Abstract: Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Abstract: Potent DBH inhibitors having the formula ##STR1## can be used to inhibit DBH activity in mammals.

Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

Abstract: 2-(N-Phenylakyl-N-formyl)amino-3-hydroxy-2-propenoic acids are intermediates for mercaptoimidazolecarboxylic acids which are dopamine-.beta.-hydroxylase inhibitors.

Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.